Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4447089
Max Phase: Preclinical
Molecular Formula: C75H130N22O16
Molecular Weight: 1596.00
Molecule Type: Unknown
Associated Items:
ID: ALA4447089
Max Phase: Preclinical
Molecular Formula: C75H130N22O16
Molecular Weight: 1596.00
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC1=O
Standard InChI: InChI=1S/C75H130N22O16/c1-43(2)38-54(60(79)102)95-71(113)75(9)33-17-13-11-10-12-16-32-74(8,70(112)94-53(30-31-59(78)101)64(106)90-55(39-44(3)4)65(107)91-56(40-45(5)6)69(111)97-75)96-68(110)52(25-21-37-85-73(82)83)89-67(109)58(42-98)93-66(108)57(41-47-26-28-48(100)29-27-47)92-63(105)51(24-20-36-84-72(80)81)88-62(104)50(23-15-19-35-77)87-61(103)49(86-46(7)99)22-14-18-34-76/h10-11,26-29,43-45,49-58,98,100H,12-25,30-42,76-77H2,1-9H3,(H2,78,101)(H2,79,102)(H,86,99)(H,87,103)(H,88,104)(H,89,109)(H,90,106)(H,91,107)(H,92,105)(H,93,108)(H,94,112)(H,95,113)(H,96,110)(H,97,111)(H4,80,81,84)(H4,82,83,85)/b11-10-/t49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,74-,75-/m0/s1
Standard InChI Key: REWHONSUJOGBSP-WVTNLIGWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1596.00 | Molecular Weight (Monoisotopic): 1595.0035 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gallagher EE, Song JM, Menon A, Mishra LD, Chmiel AF, Garner AL.. (2019) Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G., 62 (10): [PMID:31033289] [10.1021/acs.jmedchem.9b00068] |
Source(1):